Jeffrey B. Landau - 20 Dec 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Business Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Issuer symbol
CTMX
Transactions as of
20 Dec 2023
Net transactions value
-$5,628
Form type
4
Filing time
22 Dec 2023, 16:12:57 UTC
Previous filing
19 Dec 2023
Next filing
19 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Sale $5,628 -4,077 -4.5% $1.38 86,622 20 Dec 2023 Direct F1, F2
holding CTMX Common Stock 4,500 20 Dec 2023 Fidelity Traditional IRA
holding CTMX Common Stock 3,180 20 Dec 2023 Schwab ROTH IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023.
F2 Includes 52,205 restricted stock units.